Onkoloji
Anemi Tedavisi
Eritropoez Uyarıcı İlaçlar
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (yeni pencere açar)
Kaynak: Ann Oncol 2018;29(Supplement_4):iv96-110.
İndeks: PubMed 29471514
DOI: 10.1093/annonc/mdx758
https://www.ncbi.nlm.nih.gov/pubmed/29471514 (yeni pencere açar)
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (yeni pencere açar)
Kaynak: Am J Hematol 2011;86(9):762-7.
İndeks: PubMed 21850658
DOI: 10.1002/ajh.22111
https://www.ncbi.nlm.nih.gov/pubmed/21850658 (yeni pencere açar)
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (yeni pencere açar)
Kaynak: Acta Haematol 2007;117(3):162-7.
İndeks: PubMed 17148935
DOI: 10.1159/000097464
https://www.ncbi.nlm.nih.gov/pubmed/17148935 (yeni pencere açar)
Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (yeni pencere açar)
Kaynak: Am J Hematol 2013;88(12):990-6.
İndeks: PubMed 23873823
DOI: 10.1002/ajh.23552
https://www.ncbi.nlm.nih.gov/pubmed/23873823 (yeni pencere açar)
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (yeni pencere açar)
Kaynak: J Clin Oncol 2011;29(28):3791-7.
İndeks: PubMed 21860000
DOI: 10.1200/JCO.2010.30.4899
https://www.ncbi.nlm.nih.gov/pubmed/21860000 (yeni pencere açar)
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (yeni pencere açar)
Kaynak: Cancer 2012;118(3):848-55.
İndeks: PubMed 21751205
DOI: 10.1002/cncr.26341
https://www.ncbi.nlm.nih.gov/pubmed/21751205 (yeni pencere açar)
Management of anemia in cancer patients. (yeni pencere açar)
Kaynak: Future Oncol 2011;7(4):507-17.
İndeks: PubMed 21463140
DOI: 10.2217/fon.11.24
https://www.ncbi.nlm.nih.gov/pubmed/21463140 (yeni pencere açar)
Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (yeni pencere açar)
Kaynak: Acta Haematol Pol 2007;38(4):479-84.
İndeks: EMBASE 2008089811
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (yeni pencere açar)
Kaynak: Support Care Cancer 2013;21(2):485-93.
İndeks: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (yeni pencere açar)
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (yeni pencere açar)
Kaynak: BJU Int 2011;108(10):1582-7.
İndeks: PubMed 21443653
DOI: 10.1111/j.1464-410X.2011.10173.x
https://www.ncbi.nlm.nih.gov/pubmed/21443653 (yeni pencere açar)
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (yeni pencere açar)
Kaynak: J Clin Oncol 2010;28(13):2239-45.
İndeks: PubMed 20368566
DOI: 10.1200/JCO.2009.25.1835
https://www.ncbi.nlm.nih.gov/pubmed/20368566 (yeni pencere açar)
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (yeni pencere açar)
Kaynak: J Clin Oncol 2015;33(15):1674-9.
İndeks: PubMed 25870085
DOI: 10.1200/JCO.2014.57.9912
https://www.ncbi.nlm.nih.gov/pubmed/25870085 (yeni pencere açar)
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (yeni pencere açar)
Kaynak: Br J Cancer 2011;105(9):1267-72.
İndeks: PubMed 21959870
DOI: 10.1038/bjc.2011.395
https://www.ncbi.nlm.nih.gov/pubmed/21959870 (yeni pencere açar)
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (yeni pencere açar)
Kaynak: J Intern Med 2017;281(3):284-99.
İndeks: PubMed 27926979
DOI: 10.1111/joim.12579
https://www.ncbi.nlm.nih.gov/pubmed/27926979 (yeni pencere açar)
How I treat cancer-associated anemia. (yeni pencere açar)
Kaynak: Blood 2020;136(7):801-13.
İndeks: PubMed 32556170
DOI: 10.1182/blood.2019004017
https://www.ncbi.nlm.nih.gov/pubmed/32556170 (yeni pencere açar)
Update on safety of ESAs in cancer-induced anemia. (yeni pencere açar)
Kaynak: J Natl Compr Canc Netw 2012;10(5):659-66.
İndeks: PubMed 22570294
https://www.ncbi.nlm.nih.gov/pubmed/22570294 (yeni pencere açar)
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (yeni pencere açar)
Kaynak: Eur J Haematol. 2023 110(4):354-61.
İndeks: PubMed 36480004
DOI: 10.1111/ejh.13910
https://pubmed.ncbi.nlm.nih.gov/36480004/ (yeni pencere açar)
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (yeni pencere açar)
Kaynak: Int J Hematol 2015;102(4):401-12.
İndeks: PubMed 26323997
DOI: 10.1007/s12185-015-1862-5
https://www.ncbi.nlm.nih.gov/pubmed/26323997 (yeni pencere açar)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (yeni pencere açar)
Kaynak: Cancer 2013;119(1):107-14.
İndeks: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (yeni pencere açar)
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (yeni pencere açar)
Kaynak: J Natl Cancer Inst 2013;105(14):1018-26.
İndeks: PubMed 23860204
DOI: 10.1093/jnci/djt145
https://www.ncbi.nlm.nih.gov/pubmed/23860204 (yeni pencere açar)
Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (yeni pencere açar)
Kaynak: Cancer Sci 2013;104(4):481-5.
İndeks: PubMed 23331490
DOI: 10.1111/cas.12105
https://www.ncbi.nlm.nih.gov/pubmed/23331490 (yeni pencere açar)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (yeni pencere açar)
Kaynak: Br J Haematol 2019;184(2):134-60.
İndeks: PubMed 30549002
DOI: 10.1111/bjh.15707
https://www.ncbi.nlm.nih.gov/pubmed/30549002 (yeni pencere açar)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (yeni pencere açar)
Kaynak: Support Care Cancer 2012;20(1):159-65.
İndeks: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (yeni pencere açar)
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (yeni pencere açar)
Kaynak: Leuk Lymphoma. 2019;60(9):2324-7.
İndeks: PubMed 30773115
DOI: 10.1080/10428194.2019.1577414
https://www.ncbi.nlm.nih.gov/pubmed/30773115 (yeni pencere açar)
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (yeni pencere açar)
Kaynak: Oncologist 2010;15(9):935-43.
İndeks: PubMed 20798194
DOI: 10.1634/theoncologist.2009-0279
https://www.ncbi.nlm.nih.gov/pubmed/20798194 (yeni pencere açar)
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (yeni pencere açar)
Kaynak: Lung Cancer 2012;76(3):478-85.
İndeks: PubMed 22277104
DOI: 10.1016/j.lungcan.2011.12.015
https://www.ncbi.nlm.nih.gov/pubmed/22277104 (yeni pencere açar)
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (yeni pencere açar)
Kaynak: Eur J Haematol 2016;97(1):33-8.
İndeks: PubMed 26341961
DOI: 10.1111/ejh.12679
https://www.ncbi.nlm.nih.gov/pubmed/26341961 (yeni pencere açar)
İntravenöz Demir Tedavisi
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (yeni pencere açar)
Kaynak: Ann Oncol 2018;29(Supplement_4):iv96-110.
İndeks: PubMed 29471514
DOI: 10.1093/annonc/mdx758
https://www.ncbi.nlm.nih.gov/pubmed/29471514 (yeni pencere açar)
Intravenous iron in oncology. (yeni pencere açar)
Kaynak: J Natl Compr Canc Netw 2008;6(6):585-92.
İndeks: PubMed 18597712
https://www.ncbi.nlm.nih.gov/pubmed/18597712 (yeni pencere açar)
Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (yeni pencere açar)
Kaynak: J Clin Med. 2022;11(14):4156.
İndeks: PubMed 35887920
DOI: 10.3390/jcm11144156
https://pubmed.ncbi.nlm.nih.gov/35887920/ (yeni pencere açar)
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (yeni pencere açar)
Kaynak: Int J Colorectal Dis 2016;31(3):543-51.
İndeks: PubMed 26694926
DOI: 10.1007/s00384-015-2461-x
https://www.ncbi.nlm.nih.gov/pubmed/26694926 (yeni pencere açar)
How I treat cancer-associated anemia. (yeni pencere açar)
Kaynak: Blood 2020;136(7):801-13.
İndeks: PubMed 32556170
DOI: 10.1182/blood.2019004017
https://www.ncbi.nlm.nih.gov/pubmed/32556170 (yeni pencere açar)
Total dose iron dextran infusion in cancer patients: is it SaFe2+? (yeni pencere açar)
Kaynak: J Natl Compr Canc Netw 2012;10(5):669-76.
İndeks: PubMed 22570295
https://www.ncbi.nlm.nih.gov/pubmed/22570295 (yeni pencere açar)
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (yeni pencere açar)
Kaynak: Am J Hematol 2012;87(3):308-10.
İndeks: PubMed 22262486
DOI: 10.1002/ajh.22262
https://www.ncbi.nlm.nih.gov/pubmed/22262486 (yeni pencere açar)
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (yeni pencere açar)
Kaynak: Eur J Haematol. 2023 110(4):354-61.
İndeks: PubMed 36480004
DOI: 10.1111/ejh.13910
https://pubmed.ncbi.nlm.nih.gov/36480004/ (yeni pencere açar)
Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (yeni pencere açar)
Kaynak: Curr Oncol. 2023 24;30(9):7836-51.
İndeks: PubMed 37754484
DOI: 10.3390/curroncol30090569
https://pubmed.ncbi.nlm.nih.gov/37754484/ (yeni pencere açar)
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (yeni pencere açar)
Kaynak: Cochrane Database Syst Rev 2016;(2):CD009624.
İndeks: PubMed 26845108
DOI: 10.1002/14651858.CD009624.pub2
https://www.ncbi.nlm.nih.gov/pubmed/26845108 (yeni pencere açar)
Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (yeni pencere açar)
Kaynak: World J Gastroenterol 2014;20(8):1972-85.
İndeks: PubMed 24587673
DOI: 10.3748/wjg.v20.i8.1972
https://www.ncbi.nlm.nih.gov/pubmed/24587673 (yeni pencere açar)
Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (yeni pencere açar)
Kaynak: South Asian J Cancer. 2023 15;12(2):93-9.
İndeks: PubMed 37969669
DOI: 10.1055/s-0043-1771445
https://pubmed.ncbi.nlm.nih.gov/37969669/ (yeni pencere açar)
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (yeni pencere açar)
Kaynak: J Clin Oncol 2008;26(10):1619-25.
İndeks: PubMed 18375891
DOI: 10.1200/JCO.2007.12.2051
https://www.ncbi.nlm.nih.gov/pubmed/18375891 (yeni pencere açar)
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (yeni pencere açar)
Kaynak: J Cancer Res Clin Oncol 2012;138(2):179-87.
İndeks: PubMed 21972052
DOI: 10.1007/s00432-011-1072-3
https://www.ncbi.nlm.nih.gov/pubmed/21972052 (yeni pencere açar)
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (yeni pencere açar)
Kaynak: Ann Oncol 2013;24(2):475-82.
İndeks: PubMed 23071262
DOI: 10.1093/annonc/mds338
https://www.ncbi.nlm.nih.gov/pubmed/23071262 (yeni pencere açar)
Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (yeni pencere açar)
Kaynak: Am J Hematol 2024;99(7):1338-48.
İndeks: PubMed 38282557
DOI: 10.1002/ajh.27220
https://pubmed.ncbi.nlm.nih.gov/38282557/ (yeni pencere açar)